Sanuwave Health (SNWV) Financials

Sanuwave Health logo
$1.70 -0.11 (-6.08%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.64 -0.06 (-3.76%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Sanuwave Health

Annual Income Statements for Sanuwave Health

This table shows Sanuwave Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -32 12
Consolidated Net Income / (Loss)
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -33 12
Net Income / (Loss) Continuing Operations
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -32 12
Total Pre-Tax Income
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -32 12
Total Operating Income
-4.44 -3.32 -3.82 -7.18 -8.79 -25 -14 -8.95 -0.54 3.85 4.95
Total Gross Profit
0.68 0.81 0.50 1.16 0.49 2.90 8.02 12 14 25 34
Total Revenue
0.97 1.38 0.74 1.85 1.03 4.06 13 17 20 33 44
Operating Revenue
0.97 1.38 0.74 1.85 1.03 4.06 13 17 20 33 44
Total Cost of Revenue
0.28 0.57 0.24 0.69 0.54 1.16 4.99 4.33 6.04 8.08 10
Operating Cost of Revenue
0.28 0.57 0.24 0.69 0.54 1.16 4.99 4.33 6.04 8.08 10
Total Operating Expenses
5.12 4.13 4.32 8.34 9.28 28 22 21 15 21 29
Selling, General & Admin Expense
2.74 2.67 3.00 6.81 6.44 14 12 13 8.67 13 19
Marketing Expense
- - - 0.52 1.59 5.16 8.59 7.47 4.90 6.32 7.42
Research & Development Expense
2.17 1.13 1.29 0.98 1.18 1.25 1.10 0.57 0.58 0.67 1.35
Depreciation Expense
0.00 0.02 0.02 0.02 0.07 0.78 0.78 0.77 0.75 0.79 0.88
Impairment Charge
- - - - 0.00 7.19 - - - 0.00 0.20
Total Other Income / (Expense), net
-0.37 -3.12 -1.71 -4.45 -1.64 -5.74 -13 -1.34 -25 -36 7.15
Interest Expense
0.41 0.89 1.14 4.50 1.84 3.11 6.89 15 16 6.24 6.72
Other Income / (Expense), net
0.04 -2.24 -0.57 0.05 0.20 -2.63 -6.20 13 -9.64 -29 14
Income Tax Expense
- - - - - 0.00 0.03 0.00 0.00 0.03 0.09
Basic Earnings per Share
($0.08) ($0.06) ($0.04) ($0.08) ($0.05) ($0.08) ($0.05) ($0.02) ($12.19) ($7.41) $1.38
Weighted Average Basic Shares Outstanding
63.03M 107.62M 138.84M 149.54M 203.59M 378.13M 518.36M 549.47M 2.12M 4.46M 8.56M
Diluted Earnings per Share
($0.08) ($0.06) ($0.04) ($0.08) ($0.05) ($0.08) ($0.05) ($0.02) ($12.19) ($7.41) $0.41
Weighted Average Diluted Shares Outstanding
63.03M 107.62M 138.84M 149.54M 203.59M 378.13M 518.36M 549.47M 2.12M 4.46M 9.08M
Weighted Average Basic & Diluted Shares Outstanding
63.03M 107.62M 138.84M 149.54M 203.04M - - 558.64M 1.14B 8.55M 8.59M

Quarterly Income Statements for Sanuwave Health

This table shows Sanuwave Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.53 6.56 -21 -13 -6.12 0.55 9.69 6.11 -1.44 -0.68 -1.42
Consolidated Net Income / (Loss)
-4.53 6.56 -21 -13 -6.12 0.55 9.69 6.11 -1.44 -0.68 -1.42
Net Income / (Loss) Continuing Operations
-4.53 6.56 -21 -13 -6.12 0.55 9.69 6.11 -1.44 -0.68 -1.42
Total Pre-Tax Income
-4.53 6.56 -21 -13 -6.12 0.55 9.69 6.20 -1.44 -0.68 -1.35
Total Operating Income
-1.05 1.99 1.95 2.52 0.60 1.44 0.90 0.62 -1.12 -0.28 -1.07
Total Gross Profit
4.20 5.24 7.07 8.04 7.38 7.85 8.74 9.70 7.43 7.42 6.63
Total Revenue
5.79 7.16 9.36 10 9.33 10 11 13 9.62 9.74 8.58
Operating Revenue
5.79 7.16 9.36 10 9.33 10 11 13 9.62 9.74 8.58
Total Cost of Revenue
1.58 1.92 2.29 2.29 1.96 2.21 2.53 3.39 2.19 2.32 1.95
Operating Cost of Revenue
1.58 1.92 2.29 2.29 1.96 2.21 2.53 3.39 2.19 2.32 1.95
Total Operating Expenses
5.25 3.25 5.11 5.52 6.77 6.41 8.04 9.09 8.56 7.70 7.70
Selling, General & Admin Expense
3.68 1.84 2.55 3.29 4.84 4.37 5.19 6.06 5.25 4.90 5.13
Marketing Expense
1.23 1.03 2.20 1.86 1.53 1.67 2.08 2.13 2.40 1.92 1.87
Research & Development Expense
0.16 0.20 0.16 0.15 0.21 0.19 0.35 0.61 0.66 0.63 0.43
Depreciation Expense
0.18 0.18 0.21 0.22 0.19 0.17 0.22 0.29 0.25 0.25 0.27
Impairment Charge
- - 0.00 - - - 0.20 - - - 0.00
Total Other Income / (Expense), net
-3.48 4.57 -23 -15 -6.72 -0.89 8.98 5.58 -0.32 -0.40 -0.28
Interest Expense
3.67 -1.53 3.66 1.51 1.91 1.94 2.27 0.80 0.55 0.52 0.28
Other Income / (Expense), net
0.19 3.04 -19 -14 -4.81 1.05 11 6.38 0.23 0.12 -0.01
Income Tax Expense
- - - - - 0.00 0.00 - - 0.01 0.06
Basic Earnings per Share
($1.46) $2.08 ($6.49) ($0.55) ($0.72) $0.06 $1.13 $0.72 ($0.17) ($0.08) ($0.16)
Weighted Average Basic Shares Outstanding
3.10M 3.15M 3.19M 4.46M 8.55M 8.56M 8.57M 8.56M 8.59M 8.60M 8.60M
Diluted Earnings per Share
($1.46) $1.77 ($6.49) ($0.54) ($0.72) ($0.04) $0.39 $0.60 ($0.17) ($0.08) ($0.16)
Weighted Average Diluted Shares Outstanding
3.10M 3.70M 3.19M 4.46M 8.55M 9.17M 9.14M 9.08M 8.59M 8.60M 8.60M
Weighted Average Basic & Diluted Shares Outstanding
1.15B 1.18B 8.53M 8.55M 8.56M 8.57M 8.58M 8.59M 8.60M 8.60M 8.60M

Annual Cash Flow Statements for Sanuwave Health

This table details how cash moves in and out of Sanuwave Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.39 -0.02 0.60 -0.37 1.40 0.68 -1.82 0.53 0.69 8.44 1.72
Net Cash From Operating Activities
-3.47 -3.20 -1.53 -3.62 -6.41 -13 -6.41 -17 -4.54 2.46 3.88
Net Cash From Continuing Operating Activities
-3.47 -3.76 -1.89 -5.28 -6.41 -13 -6.41 -17 -4.54 2.46 3.88
Net Income / (Loss) Continuing Operations
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -33 12
Consolidated Net Income / (Loss)
-4.81 -6.44 -5.54 -12 -10 -31 -27 -10 -26 -33 12
Depreciation Expense
0.00 0.02 0.02 0.02 0.07 0.30 1.24 0.95 1.03 0.79 0.97
Amortization Expense
0.32 0.56 0.54 2.92 0.00 1.20 3.23 4.95 6.91 5.88 1.77
Non-Cash Adjustments To Reconcile Net Income
0.34 3.02 2.16 4.04 2.28 15 8.15 -12 11 27 -6.82
Changes in Operating Assets and Liabilities, net
0.67 -0.37 1.28 1.03 1.67 1.37 8.24 -1.05 2.70 2.20 -3.86
Net Cash From Investing Activities
0.10 -0.01 0.00 -0.04 -0.05 -20 -0.53 0.33 0.02 -0.49 3.43
Net Cash From Continuing Investing Activities
0.10 -0.01 0.00 -0.04 -0.05 -20 -0.53 0.33 0.02 -0.49 3.43
Purchase of Property, Plant & Equipment
0.00 -0.01 0.00 -0.04 -0.05 -0.05 -0.53 0.33 0.00 -0.49 -1.94
Divestitures
- - - - - - - - - 0.00 5.38
Net Cash From Financing Activities
0.00 3.21 2.12 3.32 7.86 33 5.12 17 5.21 6.35 -5.59
Net Cash From Continuing Financing Activities
0.00 3.21 2.12 3.32 7.86 33 5.12 17 5.21 6.35 -5.59
Repayment of Debt
0.00 -0.37 -0.04 -0.24 0.00 -5.46 -0.49 -2.98 0.00 -4.05 -30
Issuance of Debt
0.00 0.38 1.75 3.52 3.36 14 3.04 20 6.02 1.80 24
Issuance of Common Equity
0.00 3.13 - - - - - - 0.00 10 0.00
Other Financing Activities, net
0.00 0.07 0.40 0.04 4.50 22 2.57 0.56 -0.81 -1.70 0.31
Effect of Exchange Rate Changes
-0.02 -0.02 0.01 -0.02 0.00 0.00 -0.00 -0.01 - 0.12 0.00
Cash Interest Paid
0.24 0.63 0.00 0.15 0.00 0.44 2.58 3.71 1.96 4.31 3.74
Cash Income Taxes Paid
- - - - - - - - - - 0.03

Quarterly Cash Flow Statements for Sanuwave Health

This table details how cash moves in and out of Sanuwave Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1.14 -0.48 0.68 6.98 -1.74 -0.01 1.11 2.36 -1.18 -1.40 -2.81
Net Cash From Operating Activities
1.10 -0.67 1.28 0.74 -1.52 0.99 1.08 3.32 0.40 0.43 -0.85
Net Cash From Continuing Operating Activities
1.10 -0.67 1.28 0.74 -1.52 0.99 1.08 3.32 0.40 0.43 -0.85
Net Income / (Loss) Continuing Operations
-4.53 6.56 -21 -13 -6.12 1.06 10 6.11 -1.44 -0.68 -1.42
Consolidated Net Income / (Loss)
-4.53 6.56 -21 -13 -6.12 1.06 10 6.11 -1.44 -0.68 -1.42
Depreciation Expense
0.14 0.26 0.18 0.41 0.21 0.18 0.25 0.34 0.29 0.31 0.34
Amortization Expense
1.64 1.73 1.70 0.73 0.60 0.65 0.44 0.09 0.08 0.09 0.04
Non-Cash Adjustments To Reconcile Net Income
2.75 -9.08 19 11 5.91 0.67 -8.95 -4.45 1.79 1.72 1.69
Changes in Operating Assets and Liabilities, net
1.10 -0.14 1.40 0.87 -2.11 -1.56 -0.98 1.23 -0.32 -1.02 -1.51
Net Cash From Investing Activities
-0.11 -0.09 -0.05 -0.24 -0.16 -1.16 4.48 0.28 -0.16 -0.45 -0.21
Net Cash From Continuing Investing Activities
-0.11 -0.09 -0.05 -0.24 -0.16 -1.16 4.48 0.28 -0.16 -0.45 -0.21
Purchase of Property, Plant & Equipment
-0.11 -0.09 -0.05 -0.24 -0.16 -1.16 -0.53 -0.10 -0.09 -0.48 -0.24
Net Cash From Financing Activities
0.04 0.27 -0.44 6.47 -0.06 0.16 -4.45 -1.24 -1.42 -1.38 -1.75
Net Cash From Continuing Financing Activities
0.04 0.27 -0.44 6.47 -0.06 0.16 -4.45 -1.24 -1.42 -1.38 -1.75
Repayment of Debt
- - - -1.87 0.00 - -28 -1.20 -1.44 -1.44 -1.75
Cash Interest Paid
0.97 1.08 1.13 1.12 1.12 1.14 1.04 0.45 0.40 0.43 0.68
Cash Income Taxes Paid
- - - - - - - - - - 0.04

Annual Balance Sheets for Sanuwave Health

This table presents Sanuwave Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.96 1.00 1.28 1.18 3.38 23 19 20 22 30 37
Total Current Assets
0.64 0.91 1.20 1.08 2.50 7.93 4.40 6.62 9.78 18 25
Cash & Equivalents
0.15 0.13 0.73 0.36 1.76 2.44 0.62 1.15 1.80 10 12
Accounts Receivable
0.07 0.46 0.15 0.24 0.08 2.36 2.42 4.03 3.31 3.33 5.42
Inventories, net
0.28 0.23 0.23 0.36 0.54 2.96 1.04 0.87 2.95 4.15 5.93
Prepaid Expenses
0.12 0.09 0.09 0.13 0.13 0.18 0.33 0.57 1.72 0.68 1.31
Other Current Assets
- - - - - - - - - - 0.00
Plant, Property, & Equipment, net
0.00 0.08 0.06 0.08 0.09 0.47 1.01 0.86 0.94 0.30 1.97
Total Noncurrent Assets
0.32 0.01 0.01 0.02 0.78 15 13 12 12 11 11
Goodwill
- - - - 0.00 7.26 7.26 7.26 7.26 7.26 7.26
Intangible Assets
0.31 - - - 0.00 6.55 5.84 5.14 4.43 3.73 3.03
Other Noncurrent Operating Assets
0.01 0.01 0.01 0.02 0.78 0.82 0.11 - - 0.43 0.39
Other Noncurrent Nonoperating Assets
- - - - - - - - - 0.00 0.07
Total Liabilities & Shareholders' Equity
0.96 1.00 1.28 1.18 3.38 23 19 20 22 30 37
Total Liabilities
6.84 7.92 11 17 13 37 58 61 66 46 36
Total Current Liabilities
1.49 7.92 11 16 12 36 56 60 65 45 18
Short-Term Debt
0.00 5.41 5.68 9.91 5.96 15 23 39 30 25 5.64
Accounts Payable
0.51 0.71 1.81 1.59 1.44 4.45 7.64 4.40 5.71 3.73 3.25
Accrued Expenses
0.36 0.38 0.67 0.69 2.82 2.20 8.93 9.30 6.00 7.76 8.38
Other Current Liabilities
0.38 1.24 2.31 2.78 0.59 11 14 3.93 17 8.63 0.55
Other Current Nonoperating Liabilities
- 0.11 0.69 1.17 0.00 1.02 2.52 4.05 6.11 0.00 0.02
Total Noncurrent Liabilities
5.35 0.00 0.00 0.05 1.03 0.57 1.31 0.67 0.84 0.49 18
Long-Term Debt
5.35 - - - 0.00 0.14 0.88 - - 0.00 16
Other Noncurrent Operating Liabilities
- - 0.00 0.05 1.03 0.43 0.41 0.67 0.84 0.49 1.56
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-5.88 -6.91 -9.88 -15 -10 -14 -39 -41 -43 -16 1.62
Total Preferred & Common Equity
-5.88 -6.91 -9.88 -15 -10 -14 -39 -41 -43 -16 1.62
Preferred Stock
0.06 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-5.94 -6.91 -9.88 -15 -10 -14 -39 -41 -43 -16 1.62
Common Stock
-5.91 93 95 101 116 143 145 153 177 239 244
Retained Earnings
- -99 -105 -117 -126 -157 -184 -194 -220 -254 -243
Accumulated Other Comprehensive Income / (Loss)
-0.03 -0.05 -0.04 -0.06 -0.06 -0.06 -0.07 -0.07 -0.11 0.01 0.01

Quarterly Balance Sheets for Sanuwave Health

This table presents Sanuwave Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
20 23 21 22 31 33 36 37 37 33
Total Current Assets
7.39 11 8.72 9.90 19 20 23 24 23 19
Cash & Equivalents
1.10 2.94 2.46 3.26 8.50 8.50 9.60 11 9.38 6.57
Accounts Receivable
3.23 3.01 3.15 2.84 3.87 3.85 4.62 6.00 5.80 4.97
Inventories, net
1.71 2.46 2.73 3.43 5.46 5.91 6.81 5.90 7.07 6.72
Prepaid Expenses
1.36 2.43 0.38 0.38 1.01 1.91 1.60 1.27 0.95 1.00
Other Current Assets
- - - - - - - - - 0.04
Plant, Property, & Equipment, net
1.08 0.98 0.95 0.77 0.45 1.59 1.99 1.91 2.26 2.35
Total Noncurrent Assets
12 12 11 11 12 11 11 11 11 11
Goodwill
7.26 7.26 7.26 7.26 7.26 7.26 7.26 7.26 7.26 7.26
Intangible Assets
4.61 4.26 4.08 3.91 3.55 3.38 3.20 2.92 2.89 2.70
Other Noncurrent Operating Assets
- - - - 0.76 0.65 0.43 0.99 0.95 0.91
Other Noncurrent Nonoperating Assets
- - - - - - 0.08 0.06 0.05 0.00
Total Liabilities & Shareholders' Equity
20 23 21 22 31 33 36 37 37 33
Total Liabilities
86 71 61 82 48 48 39 35 34 30
Total Current Liabilities
85 70 60 82 47 47 20 18 18 16
Short-Term Debt
37 29 30 32 26 27 5.63 5.59 5.60 6.74
Accounts Payable
4.62 5.06 3.89 4.14 4.15 4.00 3.99 3.32 3.31 3.15
Accrued Expenses
6.36 6.85 4.79 5.24 3.58 3.29 3.59 8.58 8.61 5.88
Other Current Liabilities
31 22 20 38 13 12 6.37 0.79 0.64 0.62
Other Current Nonoperating Liabilities
6.10 6.90 1.24 1.60 - - - 0.02 0.02 0.01
Total Noncurrent Liabilities
0.86 0.74 0.65 0.59 0.88 1.32 19 17 16 13
Long-Term Debt
- - - - - - 18 15 14 11
Other Noncurrent Operating Liabilities
0.83 0.74 0.65 0.59 0.88 1.32 1.22 1.97 2.07 1.86
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-66 -48 -40 -60 -17 -15 -2.93 1.84 2.79 2.85
Total Preferred & Common Equity
-66 -48 -40 -60 -17 -15 -2.93 1.84 2.79 2.85
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-66 -48 -40 -60 -17 -15 -2.93 1.84 2.79 2.85
Common Stock
172 177 178 178 240 241 243 246 248 249
Retained Earnings
-238 -225 -218 -239 -257 -256 -246 -244 -245 -246
Accumulated Other Comprehensive Income / (Loss)
-0.07 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Annual Metrics And Ratios for Sanuwave Health

This table displays calculated financial ratios and metrics derived from Sanuwave Health's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
63,056,519.00 137,102,458.00 139,249,926.00 155,533,303.00 195,892,098.00 467,194,621.00 481,619,621.00 548,737,651.00 1,026,078,464.00 - 8,576,164.00
DEI Adjusted Shares Outstanding
63,056,519.00 137,102,458.00 139,249,926.00 155,533,303.00 195,892,098.00 467,194,621.00 481,619,621.00 548,737,651.00 1,026,078,464.00 - 8,576,164.00
DEI Earnings Per Adjusted Shares Outstanding
-0.08 -0.05 -0.04 -0.07 -0.05 -0.07 -0.06 -0.02 -0.03 - 1.38
Growth Metrics
- - - - - - - - - - -
Revenue Growth
13.94% 42.52% -46.33% 150.51% -44.39% 294.37% 220.68% 28.69% 21.84% 59.99% 34.99%
EBITDA Growth
21.81% -21.92% 22.86% -9.45% -103.15% -209.01% 39.71% 163.99% -122.05% -675.06% 213.86%
EBIT Growth
20.51% -26.25% 20.79% -62.23% -20.44% -223.86% 26.92% 120.94% -339.02% -136.09% 173.50%
NOPAT Growth
25.58% 25.27% -15.32% -87.75% -22.48% -186.55% 43.88% 36.70% 93.97% 1,103.15% 82.26%
Net Income Growth
19.48% -33.86% 13.99% -110.03% 10.33% -196.62% 11.89% 62.24% -150.72% -21.56% 135.71%
EPS Growth
33.33% 25.00% 33.33% -100.00% 37.50% -60.00% 37.50% 60.00% -60,850.00% 42.33% 105.53%
Operating Cash Flow Growth
47.99% 7.89% 52.21% -136.84% -77.04% -98.39% 49.61% -167.89% 73.57% 154.10% 57.88%
Free Cash Flow Firm Growth
58.22% 31.13% 103.13% -10,085.90% -6.47% -376.63% 112.52% -763.68% 145.82% -183.35% -34.94%
Invested Capital Growth
-348.90% -123.21% -178.74% -9.26% -26.37% 100.10% -214,033.33% 103.33% -2,184.31% 126.42% 1,692.30%
Revenue Q/Q Growth
16.23% 25.11% -30.97% 8.22% -10.50% 109.76% 16.07% 7.99% 7.91% 11.37% 6.70%
EBITDA Q/Q Growth
-13.01% -28.35% 7.57% 1.54% -11.87% -36.47% 24.00% 110.29% 90.78% -211.60% 443.26%
EBIT Q/Q Growth
-12.10% -28.51% 1.23% 6.54% -11.80% -39.14% 15.66% 562.43% 69.11% -381.66% 2,954.87%
NOPAT Q/Q Growth
-1.47% 5.91% -14.06% -0.28% -16.75% -68.37% 42.36% 9.17% 82.24% 37.73% 2.35%
Net Income Q/Q Growth
-22.37% -26.52% -6.23% 5.80% -7.07% -40.48% 7.50% 26.75% 48.12% -7,964.78% 267.70%
EPS Q/Q Growth
-33.33% 0.00% 0.00% 11.11% 0.00% -33.33% 28.57% 0.00% -22.02% -303.18% 139.42%
Operating Cash Flow Q/Q Growth
16.18% -0.78% -6.53% -26.80% -6.24% -10.53% 32.14% -31.27% 37.37% 472.26% 198.61%
Free Cash Flow Firm Q/Q Growth
9.99% -145.67% 100.99% -39.43% -10.40% -34.14% 127.78% -53.71% -58.30% -182.78% 79.35%
Invested Capital Q/Q Growth
-66.75% 75.09% -12.36% 15.16% 6.54% -99.23% -121.08% 0.00% 62.27% 107.88% 7.67%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
70.49% 58.93% 67.24% 62.51% 47.61% 71.36% 61.68% 74.13% 70.41% 75.23% 77.11%
EBITDA Margin
-422.10% -361.08% -518.98% -226.75% -828.44% -649.13% -122.04% 60.69% -10.99% -53.22% 48.95%
Operating Margin
-459.63% -241.01% -517.85% -388.11% -854.87% -621.15% -108.70% -53.47% -2.65% 16.60% 11.23%
EBIT Margin
-455.52% -403.51% -595.54% -385.68% -835.37% -686.00% -156.34% 25.44% -49.91% -73.65% 42.72%
Profit (Net Income) Margin
-498.22% -467.93% -749.86% -628.70% -1,013.86% -762.56% -209.52% -61.48% -126.52% -96.13% 26.82%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.10% 100.02% 100.02% 100.09% 99.28%
Interest Burden Percent
109.37% 115.97% 125.91% 163.01% 121.37% 111.16% 133.88% -241.63% 253.47% 130.42% 63.23%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.72%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 90.50%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 145.68%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -257.16%
Return on Equity (ROE)
129.50% 100.69% 65.96% 92.18% 82.06% 260.18% 103.50% 25.74% 61.31% 112.25% -166.66%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -391,834.67% 0.00% -4,573.63% 0.00% -317.27% -63.87%
Operating Return on Assets (OROA)
-156.38% -565.65% -385.19% -580.92% -376.94% -210.77% -97.68% 22.13% -48.14% -91.50% 55.79%
Return on Assets (ROA)
-171.04% -655.96% -485.00% -946.97% -457.48% -234.29% -130.91% -53.48% -122.05% -119.43% 35.02%
Return on Common Equity (ROCE)
130.60% 101.19% 65.96% 92.18% 82.06% 260.18% 103.50% 25.74% 61.31% 112.25% -166.66%
Return on Equity Simple (ROE_SIMPLE)
81.84% 93.16% 56.05% 75.74% 103.64% 225.52% 69.97% 25.10% 59.77% 246.69% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.11 -2.32 -2.68 -5.03 -6.16 -18 -9.90 -6.27 -0.38 3.79 4.91
NOPAT Margin
-321.74% -168.71% -362.49% -271.68% -598.41% -434.80% -76.09% -37.43% -1.85% 11.62% 11.14%
Net Nonoperating Expense Percent (NNEP)
48.54% 77.81% 51.91% 80.80% 57.31% 148.37% 87.13% 11.92% 67.17% 142.52% -55.17%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 2.86% 30.12% 20.82%
Cost of Revenue to Revenue
29.51% 41.07% 32.76% 37.49% 52.39% 28.64% 38.32% 25.87% 29.59% 24.77% 22.89%
SG&A Expenses to Revenue
283.29% 194.31% 406.81% 368.16% 626.02% 338.25% 89.85% 75.00% 42.52% 34.77% 43.98%
R&D to Revenue
225.05% 82.02% 175.01% 53.06% 114.89% 30.71% 8.46% 3.39% 2.84% 2.06% 3.07%
Operating Expenses to Revenue
530.12% 299.95% 585.08% 450.62% 902.49% 692.51% 170.38% 127.60% 73.06% 58.63% 66.33%
Earnings before Interest and Taxes (EBIT)
-4.40 -5.55 -4.40 -7.14 -8.59 -28 -20 4.26 -10 -24 19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.08 -4.97 -3.83 -4.20 -8.52 -26 -16 10 -2.24 -17 22
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 167.40
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.24 13.68 45.49 18.59 31.66 17.24 6.77 0.75 0.51 3.15 6.15
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.94
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.36%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 13,776.13 0.00 116.89 0.00 50.07 24.28
Enterprise Value to Revenue (EV/Rev)
9.69 17.51 52.19 23.75 35.75 20.37 8.59 2.98 1.89 3.61 6.38
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.91 0.00 0.00 13.03
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.72 0.00 0.00 14.93
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31.04 57.24
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47.95 72.50
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 830.86 0.00 0.00 0.00 37.97 0.00 4.30 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-0.91 -0.78 -0.57 -0.65 -0.59 -1.10 -0.62 -0.94 -0.69 -1.99 13.56
Long-Term Debt to Equity
-0.91 0.00 0.00 0.00 0.00 -0.01 -0.02 0.00 0.00 0.00 10.08
Financial Leverage
-0.95 -0.83 -0.66 -0.65 -0.59 -0.75 -0.76 -0.84 -0.90 -0.88 -1.77
Leverage Ratio
-0.76 -0.15 -0.14 -0.10 -0.18 -1.11 -0.79 -0.48 -0.50 -0.94 -4.76
Compound Leverage Factor
-0.83 -0.18 -0.17 -0.16 -0.22 -1.23 -1.06 1.16 -1.27 -1.23 -3.01
Debt to Total Capital
-1,009.60% -360.90% -135.09% -181.88% -145.24% 1,064.70% -164.34% -1,558.98% -226.71% 201.02% 93.13%
Short-Term Debt to Total Capital
0.00% -360.90% -135.09% -181.88% -145.24% 1,054.64% -158.40% -1,558.98% -226.71% 201.02% 23.91%
Long-Term Debt to Total Capital
-1,009.60% 0.00% 0.00% 0.00% 0.00% 10.06% -5.94% 0.00% 0.00% 0.00% 69.22%
Preferred Equity to Total Capital
-11.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
1,121.51% 460.90% 235.09% 281.88% 245.24% -964.70% 264.34% 1,658.98% 326.71% -101.02% 6.87%
Debt to EBITDA
-1.31 -1.09 -1.48 -2.36 -0.70 -0.57 -1.53 3.79 -13.37 -1.46 1.02
Net Debt to EBITDA
-1.27 -1.06 -1.29 -2.28 -0.49 -0.48 -1.49 3.68 -12.57 -0.87 0.46
Long-Term Debt to EBITDA
-1.31 0.00 0.00 0.00 0.00 -0.01 -0.06 0.00 0.00 0.00 0.76
Debt to NOPAT
-1.72 -2.33 -2.12 -1.97 -0.97 -0.86 -2.45 -6.15 -79.26 6.67 4.47
Net Debt to NOPAT
-1.67 -2.27 -1.85 -1.90 -0.68 -0.72 -2.38 -5.97 -74.51 3.97 2.04
Long-Term Debt to NOPAT
-1.72 0.00 0.00 0.00 0.00 -0.01 -0.09 0.00 0.00 0.00 3.32
Altman Z-Score
-14.84 -162.33 -133.23 -171.48 -62.20 -13.67 -19.16 -15.25 -17.18 -12.75 -1.49
Noncontrolling Interest Sharing Ratio
-0.85% -0.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.43 0.12 0.11 0.07 0.20 0.22 0.08 0.11 0.15 0.43 1.38
Quick Ratio
0.15 0.08 0.08 0.04 0.15 0.13 0.05 0.09 0.08 0.32 0.97
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.15 -1.48 0.05 -4.63 -4.93 -24 2.94 -20 8.95 -7.46 -7.39
Operating Cash Flow to CapEx
0.00% -36,481.79% 0.00% -8,443.32% -11,885.20% -23,996.23% -1,211.53% 0.00% 0.00% 501.02% 199.59%
Free Cash Flow to Firm to Interest Expense
-5.21 -1.67 0.04 -1.03 -2.69 -7.57 0.43 -1.34 0.57 -1.02 -1.10
Operating Cash Flow to Interest Expense
-8.43 -3.61 -1.34 -0.81 -3.49 -4.09 -0.93 -1.18 -0.29 0.34 0.58
Operating Cash Flow Less CapEx to Interest Expense
-8.18 -3.62 -1.34 -0.81 -3.52 -4.11 -1.01 -1.16 -0.29 0.27 0.29
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.34 1.40 0.65 1.51 0.45 0.31 0.62 0.87 0.96 1.24 1.31
Accounts Receivable Turnover
12.00 5.14 2.41 9.52 6.60 3.34 5.45 5.20 5.56 9.83 10.07
Inventory Turnover
1.02 2.19 1.04 2.35 1.20 0.66 2.50 4.54 3.16 2.28 2.00
Fixed Asset Turnover
160.01 33.91 10.76 26.79 11.98 14.36 17.55 17.93 22.74 39.08 38.73
Accounts Payable Turnover
0.77 0.92 0.19 0.41 0.36 0.39 0.82 0.72 1.19 1.71 2.89
Days Sales Outstanding (DSO)
30.41 70.99 151.56 38.33 55.27 109.38 66.93 70.24 65.70 37.15 36.25
Days Inventory Outstanding (DIO)
356.58 166.91 349.57 155.06 305.04 549.53 146.26 80.40 115.49 160.29 182.52
Days Payable Outstanding (DPO)
474.63 394.70 1,900.26 894.31 1,026.77 925.60 442.82 507.51 305.58 212.95 126.33
Cash Conversion Cycle (CCC)
-87.64 -156.80 -1,399.13 -700.92 -666.46 -266.69 -229.63 -356.87 -124.39 -15.52 92.44
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.68 -1.52 -4.25 -4.64 -5.86 0.01 -13 0.43 -8.90 2.35 12
Invested Capital Turnover
-4.73 -1.25 -0.26 -0.42 -0.20 -1.39 -2.03 -2.70 -4.81 -9.97 8.12
Increase / (Decrease) in Invested Capital
-0.96 -0.84 -2.72 -0.39 -1.22 5.87 -13 13 -9.33 11 12
Enterprise Value (EV)
9.35 24 39 44 37 83 112 50 38 118 281
Market Capitalization
4.10 19 34 34 33 70 88 13 10 103 271
Book Value per Share
($0.09) ($0.05) ($0.07) ($0.10) ($0.05) ($0.03) ($0.08) ($0.07) ($0.04) ($1.49) $0.19
Tangible Book Value per Share
($0.10) ($0.05) ($0.07) ($0.10) ($0.05) ($0.06) ($0.11) ($0.10) ($0.05) ($2.78) ($1.01)
Total Capital
-0.53 -1.50 -4.20 -5.45 -4.10 1.42 -15 -2.47 -13 13 24
Total Debt
5.35 5.41 5.68 9.91 5.96 15 24 39 30 25 22
Total Long-Term Debt
5.35 0.00 0.00 0.00 0.00 0.14 0.88 0.00 0.00 0.00 16
Net Debt
5.20 5.28 4.95 9.54 4.20 13 24 37 28 15 10
Capital Expenditures (CapEx)
-0.10 0.01 0.00 0.04 0.05 0.05 0.53 -0.33 -0.02 0.49 1.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.00 -1.72 -5.01 -5.86 -5.71 -16 -29 -16 -27 -8.88 0.46
Debt-free Net Working Capital (DFNWC)
-0.85 -1.59 -4.28 -5.50 -3.95 -13 -29 -15 -25 1.36 12
Net Working Capital (NWC)
-0.85 -7.00 -9.96 -15 -9.91 -28 -52 -54 -55 -24 6.78
Net Nonoperating Expense (NNE)
1.70 4.12 2.86 6.61 4.27 13 17 4.03 25 35 -6.90
Net Nonoperating Obligations (NNO)
5.20 5.39 5.63 11 4.20 14 26 41 34 15 9.96
Total Depreciation and Amortization (D&A)
0.32 0.58 0.57 2.94 0.07 1.50 4.46 5.90 7.94 6.67 2.74
Debt-free, Cash-free Net Working Capital to Revenue
-104.06% -125.28% -678.03% -316.74% -555.20% -386.64% -223.96% -96.82% -131.41% -27.21% 1.04%
Debt-free Net Working Capital to Revenue
-88.22% -115.57% -579.16% -297.04% -384.07% -326.57% -219.20% -89.94% -122.61% 4.16% 28.19%
Net Working Capital to Revenue
-88.22% -508.87% -1,347.97% -832.60% -963.42% -696.23% -398.64% -320.12% -269.49% -73.38% 15.39%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.08) ($0.06) ($0.04) ($0.08) ($0.05) ($0.08) ($0.05) $0.00 ($11.25) ($7.03) $1.38
Adjusted Weighted Average Basic Shares Outstanding
96.00M 138.82M 140.97M 160.32M 297.34M 378.13M 518.36M 0.00 2.12M 4.46M 8.56M
Adjusted Diluted Earnings per Share
($0.08) ($0.06) ($0.04) ($0.08) ($0.05) ($0.08) ($0.05) $0.00 ($11.25) ($7.03) $0.41
Adjusted Weighted Average Diluted Shares Outstanding
96.00M 138.82M 140.97M 160.32M 297.34M 378.13M 518.36M 0.00 2.12M 4.46M 9.08M
Adjusted Basic & Diluted Earnings per Share
($0.08) ($0.06) ($0.04) ($0.08) ($0.05) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
63.03M 107.62M 138.84M 149.54M 203.04M 0.00 0.00 0.00 3.04M 8.55M 8.59M
Normalized Net Operating Profit after Tax (NOPAT)
-3.18 -2.32 -2.68 -5.03 -6.16 -13 -9.90 -6.27 -0.38 3.79 5.10
Normalized NOPAT Margin
-328.99% -168.79% -362.49% -271.68% -598.41% -310.83% -76.09% -37.43% -1.85% 11.62% 11.59%
Pre Tax Income Margin
-498.22% -467.93% -749.86% -628.70% -1,013.86% -762.56% -209.31% -61.47% -126.50% -96.05% 27.01%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-10.67 -6.26 -3.86 -1.59 -4.68 -8.96 -2.95 0.29 -0.65 -3.29 2.80
NOPAT to Interest Expense
-7.54 -2.62 -2.35 -1.12 -3.35 -5.68 -1.44 -0.43 -0.02 0.52 0.73
EBIT Less CapEx to Interest Expense
-10.43 -6.27 -3.86 -1.60 -4.71 -8.98 -3.03 0.32 -0.65 -3.35 2.51
NOPAT Less CapEx to Interest Expense
-7.29 -2.63 -2.35 -1.13 -3.38 -5.70 -1.51 -0.41 -0.02 0.45 0.44
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sanuwave Health

This table displays calculated financial ratios and metrics derived from Sanuwave Health's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
1,140,559,527.00 1,145,974,342.00 1,181,272,961.00 - 8,548,473.00 8,555,616.00 8,568,005.00 8,576,164.00 8,594,209.00 8,598,976.00 8,602,309.00
DEI Adjusted Shares Outstanding
1,140,559,527.00 1,145,974,342.00 1,181,272,961.00 - 8,548,473.00 8,555,616.00 8,568,005.00 8,576,164.00 8,594,209.00 8,598,976.00 8,602,309.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.01 -0.02 - -0.72 0.12 1.21 0.71 -0.17 -0.08 -0.16
Growth Metrics
- - - - - - - - - - -
Revenue Growth
53.27% 53.20% 88.98% 47.62% 61.30% 41.92% 22.34% 26.81% 3.06% -3.13% -23.88%
EBITDA Growth
113.73% 1,267.55% 15.48% -144.06% -475.00% -46.42% 188.64% 163.18% 84.61% -92.56% -105.39%
EBIT Growth
90.20% 274.73% 14.40% -152.48% -387.72% -41.82% 174.84% 154.73% 78.78% -106.35% -108.86%
NOPAT Growth
46.92% 205.66% 467.80% 70.08% 157.24% -5.77% 7.31% -7.81% -287.02% -113.63% -183.10%
Net Income Growth
65.38% 190.35% 12.84% -169.91% -35.11% -83.92% 149.98% 142.25% 76.48% -223.78% -114.62%
EPS Growth
-7,200.00% 17,800.00% 34.77% 75.57% 50.68% -99.44% 107.09% 148.78% 76.39% -100.00% -141.03%
Operating Cash Flow Growth
396.50% 20.85% 162.90% 157.67% -237.91% 248.65% -15.68% 347.91% 126.17% -57.20% -178.72%
Free Cash Flow Firm Growth
244.41% -70.30% -67.16% -191.52% -414.30% -1,754.52% -613.17% -55.72% 16.51% 29.20% 88.80%
Invested Capital Growth
-57.31% 10.05% -26.53% 126.42% 101.66% 131.85% 136.02% 1,692.30% 4,651.64% 258.41% 34.36%
Revenue Q/Q Growth
-17.28% 23.78% 30.69% 10.32% -9.62% 8.80% 12.66% 14.35% -26.54% 1.25% -11.91%
EBITDA Q/Q Growth
-96.03% 672.80% -315.48% 33.83% 71.00% 224.50% 256.46% -44.65% -107.06% 147.14% -380.16%
EBIT Q/Q Growth
-104.04% 683.31% -437.62% 34.05% 67.06% 176.60% 334.28% -45.02% -112.77% 82.31% -581.65%
NOPAT Q/Q Growth
-170.81% 371.02% -31.37% 29.13% -36.94% 171.95% -21.84% -58.08% -227.94% 75.09% -282.86%
Net Income Q/Q Growth
-124.83% 244.90% -414.85% 38.29% 57.69% 118.59% 878.67% -40.83% -123.56% 52.61% -107.62%
EPS Q/Q Growth
33.94% 221.23% -466.67% 91.68% 41.46% 101.52% 4,500.00% 30.43% -128.33% 52.94% -100.00%
Operating Cash Flow Q/Q Growth
185.60% -160.73% 291.92% -42.20% -304.72% 165.46% 8.86% 207.03% -88.04% 7.05% -300.24%
Free Cash Flow Firm Q/Q Growth
-55.38% -83.50% 899.36% -224.40% -93.67% 11.51% -209.97% 70.13% -3.84% 23.80% 51.94%
Invested Capital Q/Q Growth
-65.31% 25.25% -171.38% 107.88% 133.56% 1,335.66% 206.91% 7.67% 0.16% 8.29% 15.05%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
72.62% 73.16% 75.50% 77.87% 79.02% 78.30% 77.94% 74.10% 77.25% 76.23% 77.27%
EBITDA Margin
15.69% 97.98% -161.54% -97.54% -36.48% 36.99% 117.05% 56.66% -5.45% 2.54% -8.07%
Operating Margin
-18.15% 27.81% 20.87% 24.42% 6.44% 18.47% 12.81% 4.70% -11.69% -2.88% -12.50%
EBIT Margin
-14.92% 70.29% -181.58% -108.55% -45.10% 28.82% 111.08% 53.41% -9.28% -1.62% -12.55%
Profit (Net Income) Margin
-78.26% 91.61% -220.69% -123.46% -65.55% 10.38% 90.17% 46.66% -14.96% -7.00% -16.51%
Tax Burden Percent
100.00% 100.00% 100.00% 100.21% 100.00% 100.00% 100.00% 98.61% 100.00% 100.89% 104.66%
Interest Burden Percent
524.68% 130.33% 121.54% 113.49% 145.36% 36.02% 81.17% 88.59% 161.14% 427.85% 125.63%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 38.14% -61.27% -11.03% -28.70%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 82.05% -66.05% -14.50% -33.96%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -144.84% 116.65% 33.92% 10,598.57%
Return on Equity (ROE)
34.04% 6.83% 0.62% 112.25% 106.87% 139.85% 22.29% -106.70% 55.37% 22.89% 10,569.87%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -317.27% -4,552.34% -267.33% -333.00% -63.87% -137.35% -94.03% -33.08%
Operating Return on Assets (OROA)
-16.38% 87.04% -252.26% -134.86% -60.23% 41.78% 159.66% 69.75% -12.11% -2.05% -15.23%
Return on Assets (ROA)
-85.92% 113.44% -306.60% -153.38% -87.55% 15.05% 129.60% 60.93% -19.52% -8.85% -20.03%
Return on Common Equity (ROCE)
34.04% 6.83% 0.62% 112.25% 106.87% 139.85% 22.29% -106.70% 55.37% 22.89% 10,569.87%
Return on Equity Simple (ROE_SIMPLE)
36.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.74 1.99 1.37 1.77 0.42 1.88 1.47 0.62 -0.79 -0.20 -0.75
NOPAT Margin
-12.70% 27.81% 14.61% 17.10% 4.51% 18.47% 12.81% 4.70% -8.18% -2.01% -8.75%
Net Nonoperating Expense Percent (NNEP)
9.81% -11.83% 60.52% 58.82% 25.94% 3.51% -40.17% -43.91% 4.78% 3.47% 5.27%
Return On Investment Capital (ROIC_SIMPLE)
3.93% -20.38% -4.85% 14.02% 4.81% 15.64% 7.18% 2.61% -3.51% -0.89% -3.57%
Cost of Revenue to Revenue
27.38% 26.84% 24.50% 22.13% 20.98% 21.70% 22.06% 25.91% 22.75% 23.77% 22.73%
SG&A Expenses to Revenue
63.52% 25.68% 27.19% 31.85% 51.89% 39.74% 42.01% 46.25% 54.58% 50.33% 59.83%
R&D to Revenue
2.82% 2.72% 1.72% 1.49% 2.23% 1.91% 3.01% 4.63% 6.86% 6.45% 4.97%
Operating Expenses to Revenue
90.77% 45.35% 54.64% 53.45% 72.58% 59.83% 66.84% 69.40% 88.94% 79.10% 89.77%
Earnings before Interest and Taxes (EBIT)
-0.86 5.03 -17 -11 -4.21 2.93 13 6.99 -0.89 -0.16 -1.08
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.91 7.02 -15 -10 -3.41 3.76 13 7.42 -0.52 0.25 -0.69
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 167.40 80.82 30.86 14.22
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.12 0.00 0.00 3.15 8.36 7.69 8.30 6.15 3.35 1.95 0.98
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.94 9.01 5.64 9.75
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.36% 11.10% 17.74% 10.26%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 50.07 1,310.93 91.22 33.15 24.28 13.66 7.63 3.61
Enterprise Value to Revenue (EV/Rev)
2.28 1.10 0.99 3.61 8.84 8.15 8.63 6.38 3.57 2.18 1.26
Enterprise Value to EBITDA (EV/EBITDA)
9.67 2.13 1.84 0.00 0.00 0.00 89.78 13.03 6.48 4.48 6.65
Enterprise Value to EBIT (EV/EBIT)
0.00 4.84 3.39 0.00 0.00 0.00 578.50 14.93 7.15 4.92 8.33
Enterprise Value to NOPAT (EV/NOPAT)
187.87 27.06 10.49 31.04 83.10 62.21 74.30 57.24 49.17 63.79 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 67.34 47.95 0.00 213.16 274.54 72.50 27.35 18.35 15.84
Enterprise Value to Free Cash Flow (EV/FCFF)
9.06 0.00 3.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-0.61 -0.75 -0.53 -1.99 -1.51 -1.81 -7.97 13.56 11.19 6.88 6.37
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 -6.05 10.08 8.15 4.87 4.01
Financial Leverage
-0.76 -0.77 -0.58 -0.88 -0.78 -0.86 -0.70 -1.77 -1.77 -2.34 -312.06
Leverage Ratio
-0.40 -0.40 -0.33 -0.94 -0.84 -0.99 -0.91 -4.76 -4.40 -5.81 -840.99
Compound Leverage Factor
-2.11 -0.52 -0.41 -1.07 -1.21 -0.36 -0.74 -4.22 -7.09 -24.86 -1,056.51
Debt to Total Capital
-154.78% -305.18% -113.84% 201.02% 297.74% 223.14% 114.35% 93.13% 91.80% 87.31% 86.43%
Short-Term Debt to Total Capital
-154.78% -305.18% -113.84% 201.02% 297.74% 223.14% 27.55% 23.91% 24.92% 25.49% 32.07%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 86.80% 69.22% 66.87% 61.82% 54.37%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
254.78% 405.18% 213.84% -101.02% -197.74% -123.14% -14.35% 6.87% 8.20% 12.69% 13.57%
Debt to EBITDA
5.48 2.31 2.05 -1.46 -1.12 -1.09 5.89 1.02 0.84 0.90 2.32
Net Debt to EBITDA
4.92 2.12 1.84 -0.87 -0.75 -0.74 3.47 0.46 0.40 0.46 1.48
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 4.47 0.76 0.61 0.64 1.46
Debt to NOPAT
106.46 29.41 11.65 6.67 6.76 5.21 4.87 4.47 6.39 12.77 -38.38
Net Debt to NOPAT
95.65 26.99 10.47 3.97 4.56 3.56 2.87 2.04 3.04 6.52 -24.49
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 3.70 3.32 4.65 9.04 -24.14
Altman Z-Score
-15.48 -15.48 -20.46 -11.35 -8.28 -6.55 -1.89 -2.53 -5.39 -6.48 -8.51
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.15 0.15 0.12 0.43 0.40 0.43 1.16 1.38 1.31 1.28 1.18
Quick Ratio
0.08 0.09 0.07 0.32 0.26 0.27 0.73 0.97 0.92 0.84 0.70
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4.63 0.76 7.63 -9.49 -15 -13 -39 -12 -12 -9.25 -4.44
Operating Cash Flow to CapEx
964.91% -726.09% 2,670.83% 313.98% -936.42% 85.68% 205.90% 3,457.29% 431.52% 88.91% -353.11%
Free Cash Flow to Firm to Interest Expense
1.26 0.00 2.08 -6.27 -7.61 -6.74 -17.79 -14.65 -22.23 -17.85 -16.10
Operating Cash Flow to Interest Expense
0.30 0.00 0.35 0.49 -0.79 0.53 0.49 4.16 0.73 0.82 -3.08
Operating Cash Flow Less CapEx to Interest Expense
0.27 0.00 0.34 0.33 -0.88 -0.09 0.25 4.04 0.56 -0.10 -3.96
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.10 1.24 1.39 1.24 1.34 1.45 1.44 1.31 1.31 1.26 1.21
Accounts Receivable Turnover
7.50 8.34 9.66 9.83 10.53 11.19 11.07 10.07 8.99 9.12 8.62
Inventory Turnover
3.60 3.90 3.09 2.28 2.14 2.02 1.75 2.00 1.82 1.61 1.45
Fixed Asset Turnover
25.86 24.93 31.63 39.08 50.82 30.93 29.83 38.73 37.54 22.92 19.02
Accounts Payable Turnover
1.23 1.62 1.82 1.71 1.84 2.22 2.21 2.89 2.76 2.85 2.76
Days Sales Outstanding (DSO)
48.68 43.78 37.79 37.15 34.67 32.61 32.96 36.25 40.61 40.00 42.32
Days Inventory Outstanding (DIO)
101.40 93.64 117.97 160.29 170.85 180.41 208.32 182.52 201.05 227.33 250.96
Days Payable Outstanding (DPO)
296.44 225.64 200.89 212.95 198.79 164.78 165.30 126.33 132.22 128.02 132.39
Cash Conversion Cycle (CCC)
-146.37 -88.23 -45.14 -15.52 6.73 48.24 75.99 92.44 109.44 139.32 160.89
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-15 -11 -30 2.35 0.24 3.50 11 12 12 13 14
Invested Capital Turnover
-1.86 -2.14 -1.10 -9.97 -5.00 -10.46 -4.32 8.12 7.49 5.48 3.28
Increase / (Decrease) in Invested Capital
-5.36 1.23 -6.26 11 15 15 41 12 11 9.05 3.69
Enterprise Value (EV)
51 27 29 118 320 320 356 281 158 96 52
Market Capitalization
25 0.08 0.06 103 302 301 343 271 149 86 41
Book Value per Share
($0.04) ($0.03) ($0.05) ($1.49) ($2.02) ($1.73) ($0.34) $0.19 $0.21 $0.32 $0.33
Tangible Book Value per Share
($0.05) ($0.04) ($0.06) ($2.78) ($3.29) ($2.97) ($1.56) ($1.01) ($0.97) ($0.86) ($0.83)
Total Capital
-19 -9.78 -28 13 8.75 12 20 24 22 22 21
Total Debt
29 30 32 25 26 27 23 22 21 19 18
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 18 16 15 14 11
Net Debt
26 27 29 15 18 18 14 10 9.79 9.80 12
Capital Expenditures (CapEx)
0.11 0.09 0.05 0.24 0.16 1.16 0.53 0.10 0.09 0.48 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-33 -24 -43 -8.88 -11 -8.06 -0.92 0.46 0.46 1.25 3.07
Debt-free Net Working Capital (DFNWC)
-30 -21 -40 1.36 -2.40 0.44 8.69 12 11 11 9.64
Net Working Capital (NWC)
-59 -51 -72 -24 -28 -26 3.06 6.78 5.65 5.03 2.91
Net Nonoperating Expense (NNE)
3.79 -4.57 22 15 6.54 0.82 -8.86 -5.49 0.65 0.49 0.67
Net Nonoperating Obligations (NNO)
33 29 30 15 18 18 14 9.96 9.76 9.77 12
Total Depreciation and Amortization (D&A)
1.77 1.98 1.88 1.14 0.80 0.83 0.68 0.43 0.37 0.41 0.39
Debt-free, Cash-free Net Working Capital to Revenue
-148.94% -95.88% -146.02% -27.21% -30.13% -20.55% -2.22% 1.04% 1.03% 2.84% 7.43%
Debt-free Net Working Capital to Revenue
-135.83% -86.00% -134.89% 4.16% -6.63% 1.13% 21.04% 28.19% 25.34% 24.14% 23.32%
Net Working Capital to Revenue
-264.86% -205.82% -244.37% -73.38% -78.60% -67.19% 7.40% 15.39% 12.75% 11.42% 7.03%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.01 ($6.49) ($0.55) ($0.66) $0.12 $1.20 $0.72 ($0.17) ($0.08) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding
3.10M 1.18B 3.19M 4.46M 8.55M 8.56M 8.57M 8.56M 8.59M 8.60M 8.60M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($6.49) ($0.54) ($0.66) $0.01 $0.46 $0.60 ($0.17) ($0.08) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
3.10M 1.39B 3.19M 4.46M 8.55M 9.17M 9.14M 9.08M 8.59M 8.60M 8.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
3.06M 1.18B 8.53M 8.55M 8.56M 8.57M 8.58M 8.59M 8.60M 8.60M 8.60M
Normalized Net Operating Profit after Tax (NOPAT)
-0.74 1.39 1.37 1.77 0.42 1.31 1.16 0.43 -0.79 -0.20 -0.75
Normalized NOPAT Margin
-12.70% 19.47% 14.61% 17.10% 4.51% 12.93% 10.17% 3.29% -8.18% -2.01% -8.75%
Pre Tax Income Margin
-78.26% 91.61% -220.69% -123.19% -65.55% 10.38% 90.17% 47.31% -14.96% -6.94% -15.77%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-0.24 0.00 -4.64 -7.41 -2.20 1.56 5.78 8.76 -1.64 -0.31 -3.90
NOPAT to Interest Expense
-0.20 0.00 0.37 1.17 0.22 1.00 0.67 0.77 -1.44 -0.38 -2.72
EBIT Less CapEx to Interest Expense
-0.27 0.00 -4.66 -7.57 -2.29 0.94 5.55 8.64 -1.80 -1.23 -4.78
NOPAT Less CapEx to Interest Expense
-0.23 0.00 0.36 1.01 0.14 0.38 0.43 0.65 -1.61 -1.30 -3.59
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

SANUWAVE Health’s financial profile has improved from the severe liquidity and balance-sheet stress reported in 2023 and early 2024, but the company remains unprofitable and highly leveraged relative to its equity base. Revenue has generally expanded over the period, while debt has declined substantially and shareholders’ equity returned to positive territory in 2026. However, recent earnings remain negative, cash fell during the first half of 2026, and much of the company’s operating cash flow has depended on noncash adjustments.

  • Revenue remains well above 2023 levels. Quarterly revenue increased from $4.95 million in Q3 2023 to $9.74 million in Q2 2026. Revenue also rose slightly from $9.62 million in Q1 2026, although it remained below the $13.09 million reported in Q4 2025.
  • Gross margins have remained strong. Gross profit was $7.42 million in Q2 2026, representing a margin of approximately 76%. That is consistent with margins in the 71% to 78% range across the reported periods and indicates that the company’s core products continue to generate substantial gross profit before operating expenses.
  • Operating losses narrowed sharply in 2026. Operating income improved from a $1.12 million loss in Q1 2026 to a $280,000 loss in Q2. This compares with operating income of $1.47 million in Q3 2025 and $615,000 in Q4 2025, suggesting that the recent losses are partly related to weaker revenue and elevated expenses rather than a collapse in gross margin.
  • Operating cash flow turned positive in both 2026 quarters. Cash from operations was $397,000 in Q1 2026 and $425,000 in Q2, compared with negative operating cash flow of $1.52 million in Q1 2025 and negative $668,000 in Q2 2024. This provides some support for near-term operations despite reported net losses.
  • Debt has been materially reduced. Short-term debt declined from $37.36 million in Q3 2023 and $26.77 million in Q2 2025 to $5.60 million in Q2 2026. Total reported debt, including long-term debt, was approximately $19.2 million at Q2 2026, down from roughly $32.4 million at Q1 2026 and substantially below prior-year levels.
  • Shareholders’ equity returned to positive territory. Equity was negative $60.3 million in Q3 2024 and negative $14.8 million in Q2 2025, but improved to positive $1.84 million in Q1 2026 and $2.79 million in Q2. The improvement reflects debt reduction, equity issuance and the impact of subsequent earnings, although the equity cushion remains thin.
  • Liquidity is better but not robust. Cash and equivalents totaled $9.38 million at June 30, 2026, while total current assets were $23.2 million and current liabilities were $18.2 million. The resulting current ratio was approximately 1.28, indicating coverage of near-term obligations but limited excess liquidity.
  • Capital spending has increased. Purchases of property, plant and equipment rose from $92,000 in Q1 2026 to $478,000 in Q2. Investment may support future growth, but it contributed to negative investing cash flow of approximately $448,000 in Q2.
  • The company remains unprofitable. Net losses were $1.44 million in Q1 2026 and $682,000 in Q2, compared with net income of $6.11 million in Q4 2025 and $10.33 million in Q3 2025. The earlier profits were heavily influenced by large other-income items, making them less representative of recurring operating performance.
  • Cash declined despite positive operating cash flow. Cash fell by $1.18 million in Q1 2026 and $1.40 million in Q2, primarily because of debt repayments and capital spending. The company repaid approximately $1.44 million of debt in each quarter, and Q2 cash interest paid was $427,000.

Expense control remains important. In Q2 2026, SG&A, marketing and research and development totaled approximately $7.45 million, exceeding the company’s $7.42 million gross profit before depreciation. Although these expenses declined from Q1 2026, they still left the company with a modest operating loss.

Investors should also examine the quality of the reported cash flow. Q2 2026 operating cash flow included $1.72 million of noncash adjustments and $405,000 of depreciation and amortization, partially offset by a $1.02 million use of operating working capital. This means positive operating cash flow has not yet been accompanied by consistent GAAP profitability.

Overall, SANUWAVE’s balance sheet is considerably healthier than it was in 2023-2025: debt is lower, equity is positive and operating cash flow has improved. The investment case still depends on whether the company can sustain revenue near or above current levels, reduce operating expenses enough to generate recurring profits, and preserve cash while continuing to repay debt. Restated prior-period statements and unusually large other-income and noncash items also make direct quarter-to-quarter comparisons more difficult.

11/18/26 09:12 AM ETAI Generated. May Contain Errors.

Sanuwave Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sanuwave Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sanuwave Health's net income appears to be on a downward trend, with a most recent value of $11.81 million in 2025, compared with -$4.81 million in 2015. The previous period was -$33.08 million in 2024. Find out what analysts predict for Sanuwave Health in the coming months.

Sanuwave Health's total operating income in 2025 was $4.95 million, based on the following breakdown:
  • Total Gross Profit: $33.97 million
  • Total Operating Expenses: $29.22 million

Over the last 10 years, Sanuwave Health's total revenue changed from $965.50 thousand in 2015 to $44.05 million in 2025, a change of 4,462.5%.

In the past 12 quarters, Sanuwave Health's cash and equivalents has ranged from $1.10 million in Q3 2023 to $10.78 million in Q1 2026, and is currently $6.57 million as of their latest financial filing in Q3 2026.

Sanuwave Health had total debt of $21.96 million at the end of 2025, a 13.2% decrease from 2024, and a 310.6% increase since 2015.

Over the last 10 years, Sanuwave Health's book value per share changed from -0.09 in 2015 to 0.19 in 2025.



Financial statements for NASDAQ:SNWV last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners